€287.96: 55% private expenses and 45% charged to NHS. Hospitalizations created the highest burden (22%, NHS) followed by home-care and transport (both private). In the last year 26 patients (33%) varied their occupational status due to pain. Fifty-eight (73%) patients required a caregiver; caregivers were absent from work in 80% of cases. A strong impairment in baseline HR-QoL was documented. Patients reported an average value of 37 in the EQ-VAS ('pain/discomfort' and 'usual activities' are the most impaired domains), using the UK conversion values the mean utility score was 0.07, using the Catalonian it was 0.10. According to the Oswestry questionnaire, 44% of patients were considered crippled and 39% severely disabled. The physical role was the most impaired dimension as measured with the SF-36. CONCLUSIONS: Our baseline analysis demonstrates FBSS is a very expensive disease that severely impairs HR-QoL. Future analyses will evaluate the cost-effectiveness of SCS and CMM in the treatment of FBSS.
1
IMS Health, Brussels, Belgium, 2 Janssen-Cilag AB, Sollentuna, Sweden, 3 University of Ghent, Brussels University, Ghent, Belgium OBJECTIVES: To evaluate the cost-effectiveness of fentanyl ITS (iontophoretic transdermal system-IONSYS TM ) versus epidural analgesia (EA) or intravenous patient-controlled analgesia (IV-PCA) for acute post-operative pain management (POPM) from a Finnish hospital perspective. METHODS: The cost-effectiveness of IONSYS TM was assessed using a decision analytic model estimating costs (2008€) and POPM patient outcomes (pain relief, minor and major POPM-related complications) from surgery to discharge. Groups receiving 1, 2 or 3 day(s) of IV-PCA or EA were compared to groups receiving respectively 1, 2 or 3 day(s) of IONSYS TM . Pain relief data were derived from clinical trials and published literature. Complication rates were predicted from a longitudinal hospital database. Resource use included drugs, consumables, equipment, POPM-related complications and staff time, the latter derived from expert panels and a literature review. Costs were based on official tariffs and price lists. RESULTS: The costs of IONSYS TM for 1, 2 or 3-day groups were €1,825, €2,240 and €2,655. For 1 day of IV-PCA and 1, 2, 3 day(s) of EA respectively, savings were €70, and €164, €167, €174. For 2 or 3 days of IV-PCA respectively additional costs were €19 and €105. The percentage of complication-free patients was consistently higher with IONSYS TM as regards minor and major complications with increment ranges of [1.44%, 3 .95%] and [0.04%, 2.29%], respectively. The percentage of patients reporting no or mild pain with IONSYS TM was the same as with IV-PCA and lower than with epidural with respective increments for 1, 2 and 3-day groups of -4.02%, -4.33% and -5.26%. CONCLU-SIONS: Compared to EA, IONSYS TM offers lower costs and fewer complications. EA however offers improved pain relief. Compared to IV-PCA, IONSYS TM dominates the 1-day group and for the 2 and 3-day groups offers fewer complications at a higher cost.
PSY19 MEDICAL AND COST EFFECTIVENESS OF BARIATRIC SURGERY IN OBESITY. RESULTS OF AN HTA COMMISIONED BY THE GERMAN AGENY FOR HEALTH TECHNOLOGY ASSESSMENT
Vauth C 1 , Stöber Y 1 , Bockelbrink A 2 , Greiner W 3 1 Leibniz University Hannover, Hannover, Germany, 2 Charité University Medical Center, Berlin, Germany, 3 University of Bielefeld, Bielefeld, Germany OBJECTIVES: Health Technology Assessment to evaluate the medical effectiveness and cost-effectiveness of bariatric surgical procedures in the therapy of morbid obesity in adults compared to standard interventions. METHODS: Systematic literature review (published since 2001), targeting adult subjects with morbid obesity (BMI >= 40 kg/m 2 or BMI >= 35 kg/m 2 with severe comorbidities). Relevant publications are identified by means of a structured search of 28 databases (e.g. Medline, Embase, Cochrane Central) on November 12 th , 2007. In addition a manual search of identified reference lists was conducted. Titles and abstracts of the identified publications have been independently screened by two experts on evidence based medicine and health economics. The methodological quality of included studies have been assessed using the criteria recommended by the Scottish Intercollegiate Guideline Network (SIGN) Grading Review Group. Randomised as well as non-randomised studies are included, case reports and series are not considered. The methodological quality of the economic publications has been assesed using checklists of the German Scientific Working Group of Technology Assessment for Health Care and the methodological guide of the EURONHEED project. RESULTS: Among 5910 retrieved publications, 25 medical articles and seven health economic studies met the inclusion criteria. Among the included medical publications are nine RCTs, 13 papers on nonrandomised clinical trials, and three systematic reviews with meta-analysis. Within the economic assessment, three CEA and four systematic reviews have been identified. Three of the nonrandomised studies assess bariatric vs. conventional procedures. All other studies compare different surgical procedures among each other. Follow-up time varies between one and five years in the RCT and goes up to eleven years in one clinical trial. Both medical studies assessing effectiveness of bariatric vs. conventional procedures show a significant greater weight loss after surgery and decline in comorbidities. Diabetes incidence after ten years is lower in the surgery group, but no significant differences can be seen for hypertension, dislipoproteinemia. Among the economics publications, three studies evaluated the costeffectiveness of certain bariatric surgeries. One study examined two bariatric operations, adjustable gastric banding and gastric bypass, for the treatment of obesity in patients with Type 2 diabetes mellitusOne of the studies included deals with a comparison of GBP vs. no treatment, whereas the other compares the two surgical procedures VBG and AGB among each other. Furthermore, four systematic literature reviews are among the included economic publications, estimating the cost-effectiveness of bariatric treatments based on published data. The focus of the reviews lies both, on the comparison of the cost-effectiveness among the bariatric procedures, as well as on the comparison to no treatment at all. CONCLUSIONS: The short and medium term effectiveness of bariatric procedures on weight loss can be assumed and is cost-effective. The weight loss is generally accompanied by a reduction of comorbidities, in particular diabetes, and a decreased overall mortality. There is a lack of studies that focus long term effects and costs. Therefore, based on the available literature no recommendation can be given with respect to the choice of a certain bariatric procedure in usual care or to the A634 Abstracts selection of particular groups of patients. However, the present results can be seen as a basis for discussion about the very restrictive practice regarding decisions on reinbursability of bariatric procedures. Further more, comprehensive quality assurance is needed, including the implementation of competence centres and the fixing of minimum amounts for procedures. In this context the long term assessment and evaluation of all patients and their course of disease is necessary, aiming at the highest possible effectiveness of medical treatment and still allowing for economic limits. The aim of this research was to evaluate the cost-effectiveness of duloxetine as an additional treatment option in the management of fibromyalgia (FM), assessed from an NHS Scotland health care system perspective. METHODS: We used a 3-year health state transition model to represent the sequential drug management of patients with FM. Guidelines, evidence reviews and clinical opinion were used to define a standard treatment for Scotland based on tricyclic antidepressants (TCAs) with switching to second-generation antidepressants (SSRIs or SNRIs). The model considered two levels of pain response based on an 11-point severity scale (0 = 'no pain' to 10 = 'worst pain possible'): Ն30% (response) and Ն50% (full response) change from baseline score. Clinical efficacy and discontinuation data were taken from a systematic literature review and an adjusted indirect meta-analysis based on placebo-controlled trials of FM treatments. Utility data were linked to pain severity using trialbased EQ-5D data collected from patients in the duloxetine studies. Costing was based on 2006. Annual discounting was applied equally at 3.5%. RESULTS: The first-line use of duloxetine resulted in approximately 67 additional quality-adjusted life years (QALYs) per 1000 patients, achieved at an additional cost of £397,360. This corresponded to a cost per QALY of £5950 compared to current standard treatment without duloxetine. These results were robust to both deterministic and probabilistic sensitivity analyses, demonstrating a 70% probability of the ICER falling below £15,000 per QALY. A step-wise analysis reported a cost per QALY of £4847 for first-line duloxetine versus second-line treatment and £7360 versus third-line treatment. CONCLUSIONS: There is currently a significant unmet need for patients with poorly controlled FM where pain is a predominant symptom. These analyses show that the introduction of duloxetine into the standard treatment sequence for FM could provide additional patient benefits which should be considered cost-effective when compared to commonly adopted thresholds.
PSY20 THE COST EFFECTIVENESS OF DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN THE NHS IN SCOTLAND

PSY21
COST-MINIMIZATION ANALYSIS OF ORAL VS. INTRAVENOUS FLUDARABINE (BENEFLUR®) IN SPAIN
Delgado J 1 , Febrer L 2 , Nieves D 3 , Piñol C 2 , Brosa M 3 1 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2 Bayer HealthCare, Barcelona, Spain, 3 Oblikue Consulting, Barcelona, Spain OBJECTIVES: Beneflur ® , whose active principle is fludarabine, has an oral and an intravenous (i.v.) formulation. The objective of the present study was to compare the efficiency of both formulations by means of a cost-minimization analysis in the treatment of B-cell chronic lymphocytic leukaemia (CLL) in Spain. METHODS: Existence of previous clinical evidence on the therapeutic equivalence between both fludarabine formulations justified a cost-minimization analysis to compare efficiency. The National Health System (NHS) perspective was taken including only direct costs. Also indirect costs were considered allowing a societal viewpoint. Data on resources use were obtained from published literature and through an expert panel. Unit costs were obtained from Spanish costs databases. Generic i.v. fludarabine cost was used. The model was built in Microsoft Excel and a sensitivity analysis by means of two different techniques (scenario analysis and Monte-Carlo Simulation) was performed to ensure robustness of results. RESULTS: Although acquisition costs for oral fludarabine are higher than for i.v. fludarabine, higher administration costs for the i.v. formulation due to hospital administration and adverse event costs compensate them, resulting in net savings for the NHS of €2152 and €1322 using the oral formulation (baseline scenario), in monotherapy and in combined therapy respectively. The range of savings obtained through the scenario analysis was: Ն€1024 Յ€3280 for monotherapy and Ն€617 Յ€2027 for combined therapy. Indirect costs, i.e. lost productivity, charge only i.v. fludarabine, adding extra savings to the oral formulation. Monte-Carlo results confirmed model robustness. CONCLUSIONS: Oral fludarabine has equivalent efficacy and an improved safety profile than intravenous fludarabine showing total lower costs both in monotherapy and in combination with cyclophosphamide, from the perspective of the National Health System in Spain. Hence, oral fludarabine should be administered instead of intravenous fludarabine unless contra-indicated.
